Concepedia

Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes

Ju Young Kim, Seong‐Kyu Lee, Kyung-Jin Jo, Dae‐Yong Song, Dong-Mee Lim, Keun-Young Park, Lynda F. Bonewald, Byung-Joon Kim

Life Sciences · 2013 · 132 citations · 33 references

DOI

Concepts

References

33

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

D. G. Winkler · The EMBO Journal · 2003 · 1.1K citations · Full text

, , +13

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Kenneth Poole, Rutger L. van Bezooijen, N. Loveridge et al. · The FASEB Journal · 2005 · 962 citations

, , +16

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Tina Vilsbøll, Thure Krarup, Carolyn F. Deacon et al. · Diabetes · 2001 · 884 citations · Full text

, , +16

Establishment of an Osteocyte-like Cell Line, MLO-Y4

Yoichi Kato, Jolene J. Windle, Barbara A. Koop et al. · Journal of Bone and Mineral Research · 1997 · 556 citations

, , +12

Effects of Diabetes Mellitus on Bone Mass in Juvenile and Adult-Onset Diabetes

Marvin E. Levin, Vincenza C. Boisseau, Louis V. Avioli · New England Journal of Medicine · 1976 · 523 citations

, , +13